Therapeutic outcome and safety of intralesional vitamin d3 in the treatment of cutaneous warts

Authors : Anshu Maheswari, Atul Bothra, Pankaj Adhicari, Bornali Dutta, Seujee Das

DOI : 10.18231/j.ijced.2022.010

Volume : 8

Issue : 1

Year : 2022

Page No : 47-50

Introduction: Cutaneous warts are a common but vexing condition with high recurrence rate and tendency to spread inspite of various therapeutic options. Intralesional immunotherapy is an attractive modality as it has an additional role of clearing both treated and distant warts by stimulating cell-mediated immunity against human papilloma virus.
Aims and Objectives: To evaluate efficacy and safety profile of intralesional Vitamin D3 formulation in the treatment of cutaneous warts.
Materials and Methods: Patients with multiple cutaneous warts were injected intralesionally with Vitamin D3 (0.2 ml, 15 mg/ml) at an interval of 2 weeks for maximum of 4 sessions, and patients were followed up for 6 months.
Results : Of the 106 patients included, complete clearance was seen in 26 (76.4 %) patients of verruca vulgaris, 20 (66.6 %) of palmoplantar warts, 18 (100 %) of plane warts, 6 (50 %) of genital and filiform warts each. Moderate response was seen in 14 (13.2%) patients while mild response was seen in 6 (5.7 %) patients. No response was seen in 10 (9.4 %) patients. No serious adverse effects were reported.
Conclusion: Intralesional Vitamin D3 is effective, safe, cheap and long lasting modality with a short downtime for the treatment of multiple cutaneous warts.
 

Keywords: Cutaneous Warts, Intralesional treatment, Vitamin D3, Immunotherapy


Citation Data